# Strategic Feedback — GPT-5.4 (R1)

**Role:** Journal editor (AER perspective)
**Model:** openai/gpt-5.4
**Timestamp:** 2026-03-30T10:58:57.937663
**Route:** OpenRouter + LaTeX
**Tokens:** 11717 in / 3718 out
**Response SHA256:** 042d55e4cac1d5ae

---

## 1. THE ELEVATOR PITCH

This paper asks whether mandatory disclosure rules actually make science more transparent. Using the exemption of Phase 1 clinical trials from the 2007 FDA Amendments Act, it studies whether legally mandated registration and results reporting increased the share of trials that publicly post results, and whether the response is concentrated where enforcement is credible.

A busy economist should care because this is not really a paper about clinical medicine; it is a paper about whether regulation can correct selective disclosure in the production of knowledge. That question travels well: it speaks to market design, information disclosure, regulation, and the current metascience debate over preregistration and the file-drawer problem.

**Does the paper itself articulate this pitch clearly in the first two paragraphs?**  
Not quite. The current opening is vivid and morally urgent, but it starts as a broad indictment of selective reporting in medicine rather than as a sharply framed economics question. The economics hook only arrives later, and the paper's strongest angle — mandatory transparency as regulation of an information market — is underplayed early.

**What the first two paragraphs should say instead:**

> Scientific evidence is an economic object: it is produced by agents with incentives, and when unfavorable findings can be withheld, the public signal becomes systematically biased. Clinical trials are a first-order setting for this problem because suppressed or selectively reported results distort treatment decisions, investment, and regulation. The policy question is whether transparency mandates actually change disclosure behavior, or whether selective reporting simply adapts to the new rules.
>
> This paper studies that question using the FDA Amendments Act of 2007, which required Phase 2 and Phase 3 trials to register and report results on ClinicalTrials.gov while exempting Phase 1 trials. Comparing reporting behavior across exempt and non-exempt phases before and after the law, I ask whether mandatory disclosure increases the public availability of scientific evidence, and whether any effect appears precisely where legal enforcement is credible — among industry-sponsored and U.S.-connected trials.

That is the pitch the paper should lead with.

---

## 2. CONTRIBUTION CLARITY

**Contribution in one sentence:**  
The paper argues that clinical-trial transparency mandates increase public results reporting, with effects concentrated in settings where enforcement is credible, suggesting that disclosure regulation can change the supply of scientific evidence.

### Is this contribution clearly differentiated from the closest 3-4 papers?
Only partially. The paper says it is the “first causal estimate,” which is useful, but “first causal estimate” is not enough by itself for AER positioning. It needs to be much clearer about what the descriptive compliance literature could not tell us and what economics insight this paper adds beyond documenting undercompliance. Right now the contribution risks sounding like: “take known compliance problem, apply DiD.”

The differentiation should be against:
- descriptive compliance papers on ClinicalTrials.gov;
- medical literature on publication bias and registry use;
- economics papers on mandatory disclosure in other markets;
- metascience papers on preregistration and credibility.

It needs a firmer sentence like: **existing papers document noncompliance and selective publication; this paper asks whether legal disclosure mandates alter disclosure behavior, and whether enforcement capacity rather than transparency norms is the active ingredient.**

### Is the contribution framed as answering a question about the world, or as filling a gap in a literature?
Mixed, but too often as a literature gap. The stronger version is a world question:

- Weak framing: “There is no causal estimate of FDAAA 801.”
- Strong framing: “When can the state force the production of unbiased public knowledge?”

The latter is much more AER-relevant.

### Could a smart economist who reads the introduction explain to a colleague what’s new?
At present, maybe, but with some hesitation. They might say:  
“It's a DiD on FDAAA showing reporting went up, especially for industry.”

That is not yet enough. You want them to say:  
“It shows transparency mandates matter mainly when backed by real enforcement, so voluntary disclosure norms may not fix selective reporting.”

That version is memorable and portable.

### What would make this contribution bigger?
Several specific possibilities:

1. **Lean harder into enforcement as the central object.**  
   Right now enforcement shows up as heterogeneity. It should be the paper’s main conceptual contribution. The big question is not “did FDAAA matter?” but “does disclosure regulation work only when noncompliance has real downstream consequences?”

2. **Focus on the most policy-relevant outcome.**  
   The “number of primary outcomes” mechanism is not pulling its weight. It feels secondary, noisy, and conceptually underdeveloped. A bigger paper would study outcomes tied more directly to information quality: timeliness of reporting, publication versus registry disclosure, reporting of null findings, concordance between registration and posted outcomes, or whether posted results fill known gaps in the evidence base.

3. **Clarify whether this is about scientific production or public disclosure.**  
   Those are distinct claims. The paper currently slides between them. The compelling and defensible contribution is about disclosure behavior. The bigger ambition — changing the production of evidence — would require outcomes that genuinely measure that.

4. **Reframe toward general equilibrium beliefs about voluntary transparency.**  
   The bridge to economics preregistration is potentially high-return, but currently too glib. If developed carefully, the paper could become a broader statement about the limits of norm-based governance versus legally enforceable disclosure.

---

## 3. LITERATURE POSITIONING

### Closest neighbors
The paper’s nearest neighbors seem to be:

1. **Prayle, Hurley, and Smyth (2012)** on compliance with FDAAA reporting requirements.  
2. **Anderson et al. (2015)** on compliance with results reporting at ClinicalTrials.gov.  
3. **DeVito et al. (2020)** on trends in compliance/reporting over time.  
4. **Turner et al. (2008)** on selective publication of antidepressant trials.  
5. On the economics side, **Dranove and Jin (2010)** and related work on information disclosure/quality disclosure in health care and markets.

Also relevant:
- **Chan et al. (2004)** and **Dwan et al. (2008)** on outcome switching/publication bias.
- **Olken (2015)**, **Nosek et al. (2015)**, **Christensen and Miguel**, and broader metascience/preregistration papers.
- Possibly the regulatory disclosure literature in finance and environmental economics, if the paper wants breadth.

### How should the paper position itself relative to those neighbors?
**Build on and connect, not attack.**  
The medical literature established the problem and documented descriptive compliance failures. This paper should say: *that literature showed the system was broken; I ask what legal disclosure rules actually changed, and for whom.* That is a natural step forward.

Relative to the disclosure literature in economics, the paper should position itself as **extending mandatory disclosure into a new market: the market for scientific evidence itself.** That is a stronger and more original angle than just saying “this is like healthcare report cards.”

Relative to metascience/preregistration papers, it should be careful. It should not overclaim that evidence from FDA-regulated clinical trials directly answers whether AEA registries work. The right move is: *this is a disciplined case study showing that compliance responds to enforceability, which is informative for the design of transparency institutions more broadly.*

### Is the paper currently positioned too narrowly or too broadly?
Oddly, both.

- **Too narrowly** in the sense that much of the paper is written as a clinical-trials compliance study.
- **Too broadly** when it jumps to sweeping conclusions about preregistration in economics.

It needs a middle path: **a paper about regulation of scientific disclosure, using clinical trials as the sharpest institutional setting.**

### What literature does the paper seem unaware of?
It feels underconnected to:
- the broader economics of regulation and compliance;
- legal/institutional work on enforceability versus symbolic mandates;
- metascience literature on registry-based evidence production, beyond the usual transparency citations;
- potentially the literature on public goods and information externalities.

The paper should probably also engage the idea that **scientific evidence is a credence good with disclosure frictions**, which could bring in industrial organization / information economics readers.

### Is the paper having the right conversation?
Not yet fully. The current conversation is: “clinical trial transparency, compliance, preregistration.”  
The higher-impact conversation is: **“What makes disclosure regulation effective when the regulated output is information rather than a physical product?”**

That is the right conversation for AER.

---

## 4. NARRATIVE ARC

### Setup
Before the paper, we know selective reporting is pervasive in clinical research, distorting the evidence physicians and regulators observe. We also know FDAAA created a formal disclosure regime, but compliance remained imperfect and descriptive evidence alone cannot tell us whether the law changed behavior.

### Tension
There are two tensions, and the paper only partly exploits them:

1. **Can legal disclosure mandates actually force hidden information into the public domain?**
2. **Or are transparency rules mostly symbolic unless backed by credible enforcement?**

The second is the stronger one.

### Resolution
The paper’s resolution is: reporting rises after the mandate, especially for industry-sponsored and U.S.-linked trials, which suggests the law matters most where enforcement is salient.

### Implications
The implication is that transparency in science is not self-enforcing; institutional design and enforcement capacity matter. That matters for clinical regulation and, more broadly, for how economists think about preregistration and disclosure institutions.

### Does the paper have a clear narrative arc?
It has the ingredients, but the arc is muddled by two things:

1. It starts as a paper about selective reporting in medicine.
2. It ends as a paper about enforcement and lessons for economics.

Those are connected, but the paper does not cleanly guide the reader from one to the other. The mechanism section on primary outcomes further diffuses the storyline rather than strengthening it.

### If it is a collection of results looking for a story, what story should it be telling?
The story should be:

- **Setup:** Selective disclosure corrupts the information environment in science.
- **Tension:** Policymakers increasingly rely on disclosure mandates, but we know little about whether they work — and especially whether they work absent enforcement.
- **Resolution:** FDAAA increased disclosure where regulated actors faced meaningful legal/regulatory consequences.
- **Implication:** In knowledge markets, transparency rules are not enough; enforceable transparency is the operative institution.

That is a clean AER-style narrative. Right now the paper is close to it, but not disciplined enough.

---

## 5. THE “SO WHAT?” TEST

### What fact would I lead with at a dinner party of economists?
I would say:  
**“When clinical-trial reporting became mandatory, disclosure rose sharply only among sponsors for whom the mandate had teeth.”**

That is the memorable fact.

### Would people lean in or reach for their phones?
Some would lean in — especially people interested in information economics, health, regulation, and metascience — but not yet all of them. The topic is important, but the current packaging makes it sound more specialized than it needs to.

### What follow-up question would they ask?
Probably:  
**“So is the real result that enforcement matters, not transparency per se?”**

That is exactly the question the paper should be designed to answer.

A second follow-up would be:  
**“Does this improve the quality of the evidence base, or just the rate of posting?”**

The paper currently has only a partial answer to that.

### If findings are modest: is the result itself interesting?
Yes, but only if framed correctly. A 10 percentage point pooled effect is not huge on its own, and the paper itself spends real effort warning against overinterpreting it. The more interesting finding is the **selective response by industry / U.S. exposure**, because that says something sharper about institutional design.

The paper does make a decent case that “voluntary norms are weak, enforcement matters” is interesting. But to avoid feeling like a compromised DiD with some heterogeneity tables attached, it needs to put that message front and center.

---

## 6. STRUCTURAL SUGGESTIONS

### What would make it read better?

1. **Rewrite the introduction around one question.**  
   Right now the introduction tries to do three things at once:
   - document the moral importance of selective reporting,
   - present the design,
   - defend the design against its own limitations.
   
   The result is slightly defensive and cluttered. The intro should instead deliver:
   - the big question,
   - the natural experiment,
   - the headline finding,
   - why it matters beyond this setting.

2. **Move some caveats out of the introduction.**  
   The introduction currently gives away too much methodological throat-clearing too early. It is good that the paper is honest, but the strategic cost is high. A reader should first understand the question and why the answer matters.

3. **Front-load the heterogeneity result.**  
   The industry/non-industry split is arguably the most interesting finding and may be the real intellectual core. It belongs in the introduction and perhaps in the first results table or figure, not as a secondary add-on.

4. **Demote or rethink the primary-outcomes mechanism section.**  
   As currently framed, it muddies rather than clarifies. It introduces a second claim — about research design discipline — that the paper cannot really cash out. If kept, it should be much shorter and more cautious, maybe even appendix/main-text-short-form. If the authors cannot make a compelling conceptual case for this outcome, cut it.

5. **Use a figure early.**  
   This paper badly wants one simple figure showing reporting rates by phase over time, plus maybe sponsor splits. Readers should see the pattern quickly.

6. **Shorten institutional background.**  
   It is useful but slightly overexplained. AER readers do not need a mini medical-ethics essay. Trim and use the saved space to sharpen positioning.

7. **Conclusion should do more than summarize.**  
   The conclusion currently mostly restates findings. It should instead answer: what does this imply for the design of disclosure regimes in science and other information markets?

### Is the paper front-loaded with the good stuff?
Somewhat, but not enough. The good stuff is there by page 3-4, but the reader still has to wade through too much setup before the main economic idea becomes clear.

### Are there results buried in robustness that should be in the main results?
Yes. The paper’s own robustness section contains the tension that defines the paper: the pooled estimate is fragile, but the pattern across enforcement-relevant margins is more compelling. That is not mere robustness; it is the paper’s substantive message.

### Is the conclusion adding value or just summarizing?
Mostly summarizing. It should instead elevate the paper from “compliance study” to “institutional design of transparency.”

---

## 7. WHAT WOULD MAKE THIS AN AER PAPER?

The gap is mainly a **framing and ambition problem**, with some **scope** concerns.

### Framing problem
The science is not being sold in the strongest terms. The paper is currently framed as:
- a clinical-trials transparency paper,
- using a standard reduced-form design,
- with a somewhat compromised headline estimate,
- and a broad but not fully earned jump to economics preregistration.

That is not enough.

The stronger frame is:
- a paper on **mandatory disclosure in the production of knowledge**,
- showing that **enforcement is the key margin**,
- in one of the most consequential settings for public decision-making.

### Scope problem
The current scope is a little narrow for AER unless the enforcement angle is developed much more forcefully. If the paper remains mostly “did reporting increase?”, it feels field-journal-plus. To feel like AER, it should either:
- deepen the evidence on why enforcement is the operative mechanism, or
- broaden the implications for information disclosure and metascience in a disciplined way.

### Novelty problem
There is some novelty, but not yet enough perceived novelty. “First causal estimate” helps, but top journals do not publish methods novelty alone. The paper needs the broader conceptual novelty: **scientific evidence as a regulated information market**.

### Ambition problem
The paper is competent but slightly safe. It understates the truly interesting question it has in hand. It also overextends in a less productive direction by making broad claims about economics preregistration without enough bridge-building.

### Single most impactful piece of advice
**Rebuild the paper around the proposition that disclosure mandates work only when backed by credible enforcement, and treat clinical trials as the leading case of how regulation shapes the supply of scientific evidence.**

If they do only one thing, it should be that.

---

### Strategic Assessment

- **Current framing quality:** Adequate
- **Contribution clarity:** Somewhat fuzzy
- **Literature positioning:** Could be stronger
- **Narrative arc:** Serviceable
- **AER distance:** Medium
- **Single biggest improvement:** Reframe the paper from a clinical-trials compliance study into a broader economics paper about enforceable disclosure and the regulation of scientific evidence.